---
title: "Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280690969.md"
description: "Oramed Pharmaceuticals reported $2.0 million in revenue for 2025, primarily from the HTIT license settlement, with a diluted EPS of $1.50. The company achieved a net income of $64.016 million due to significant non-operating revaluation gains, despite an operating loss of $15.088 million and minimal gross profit. Strategic shifts include transferring R&D responsibilities and entering joint activities to enhance operational focus and liquidity."
datetime: "2026-03-26T21:25:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280690969.md)
  - [en](https://longbridge.com/en/news/280690969.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280690969.md)
---

# Oramed Pharmaceuticals 2025 10-K: $2.0M Revenue, $1.50 Diluted EPS

Oramed Pharmaceuticals reported $2.0 million of revenue in 2025 related to the HTIT license settlement and delivered diluted earnings per share of $1.50, results driven by a significant non-operating revaluation gain that produced a $64.016 million net income. Operating performance remained negative, with an operating loss of $15.088 million and minimal gross profit reported. The company continues to reposition its R&D and operational activities through strategic transactions and collaborations.

**Financial Highlights**

-   **Revenues:** $2.0 million, recognized in 2025 related to the HTIT License Agreement.
-   **Gross Profit:** $0.013 million, driven by $1.987 million cost of revenue (IIA payment) in 2025.
-   **Operating Loss:** $(15.088) million, reported as Operating Loss.
-   **Net Income:** $64.016 million, reflecting large financial income (revaluation gains) net of tax.
-   **Diluted income (loss) per share of common stock:** $1.50 for the year ended December 31, 2025.

**Business Highlights**

-   **Revenue Recognition Shift:** Recognized $2.0 million in 2025 from settlement of the HTIT license, representing the first material revenue after prior years of minimal sales.
-   **R&D Focus and Asset Transfers:** Transferred POD technology and future R&D responsibilities to OraTech/Lifeward; OraTech will bear future oral insulin trial costs.
-   **Strategic Investments and Joint Activity:** Entered into Lifeward share purchase and notes transactions, acquiring equity, warrants and revenue-sharing rights as part of broader strategic positioning.
-   **Clinical Operations Arrangement:** Agreed to manage an OraTech clinical trial under a Clinical Trial Management Agreement with reimbursement for services provided.
-   **Operational Liquidity and Corporate Strategy:** Continued share repurchase activity and redirected operational focus toward strategic reviews, potential pipeline moves, and partnerships.

Original SEC Filing: ORAMED PHARMACEUTICALS INC. \[ ORMP \] - 10-K - Mar. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ORMP.US](https://longbridge.com/en/quote/ORMP.US.md)

## Related News & Research

- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)
- [Eli Lilly Among Petitioners Denied Certiorari as Supreme Court Rejects Multiple Appeals](https://longbridge.com/en/news/286789989.md)